Triapine for Uterine Cancer
Trial Summary
What is the purpose of this trial?
This early phase I trial investigates the response to the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and bilateral salpingo-oophorectomy). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding triapine to the usual approach of surgery followed by chemotherapy alone or in combination with radiation therapy may help to slow the growth of uterine cancer.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot take medications that are inhibitors or inducers of triapine, or those associated with methemoglobinemia. You will be counseled on potential drug interactions during the enrollment process.
What data supports the idea that Triapine for Uterine Cancer is an effective treatment?
The available research shows that Triapine has been studied for its effectiveness in treating cervical cancer, which is similar to uterine cancer. In clinical trials, Triapine was combined with another drug, cisplatin, and radiation therapy, and it helped control the disease over a long period. However, some studies suggest that Triapine alone may not be very effective against solid tumors due to its short time in the body and quick breakdown. Researchers are exploring ways to improve its effectiveness, such as using special carriers to deliver the drug more efficiently. While there is promising data for cervical cancer, specific data for uterine cancer is not provided in the available research.12345
What safety data is available for Triapine in treating cancer?
Triapine, also known as 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, has been evaluated in several clinical trials for its safety and efficacy. A Phase I trial identified dose-limiting toxicities and the maximum-tolerated dose for a 96-hour intravenous infusion in patients with advanced cancer. Additionally, Triapine has been studied in combination with cisplatin radiochemotherapy for cervical cancer, showing long-term disease control. However, challenges such as short plasma half-life and fast metabolism have been noted, leading to research into liposomal formulations to improve its pharmacokinetic properties. Overall, Triapine has been shown to enhance radiochemosensitivity and induce apoptosis in cancer cells, but further studies are needed to optimize its delivery and efficacy.12346
Is the drug Triapine a promising treatment for uterine cancer?
Research Team
Rebecca L Stone
Principal Investigator
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Eligibility Criteria
This trial is for adults with specific types of uterine cancer who are planning to have a hysterectomy and haven't had previous cancer treatment. They must be in good health overall, with proper kidney, liver, and blood cell function. People with certain heart conditions or infections like hepatitis B or C need to have them under control. Pregnant women can't join, and participants should understand the study well enough to consent.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Triapine (Ribonucleotide Reductase Inhibitor)
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School